
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2134551/publications.pdf Version: 2024-02-01



VEDA RITTNED

#	Article	IF	CITATIONS
1	Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction. Journal of Clinical Lipidology, 2022, 16, 75-82.	0.6	2
2	Hybrid cardiac rehabilitation – The state of the science and the way forward. Progress in Cardiovascular Diseases, 2022, 70, 175-182.	1.6	12
3	Association of participation in Cardiac Rehabilitation with Social Vulnerability Index: The behavioral risk factor surveillance system. Progress in Cardiovascular Diseases, 2022, 71, 86-91.	1.6	8
4	Alirocumab after acute coronary syndrome in patients with a history of heart failure. European Heart Journal, 2022, 43, 1554-1565.	1.0	23
5	Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White Adults With Cardiovascular Disease. Journal of the American Heart Association, 2022, 11, .	1.6	7
6	Trends in Recurrent Coronary Heart Disease After Myocardial Infarction Among US Women and Men Between 2008 and 2017. Circulation, 2021, 143, 650-660.	1.6	48
7	Risk for recurrent cardiovascular disease events among patients with diabetes and chronic kidney disease. Cardiovascular Diabetology, 2021, 20, 58.	2.7	7
8	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol. Circulation, 2021, 143, 1109-1122.	1.6	46
9	Prior Oral Contraceptive Use and Longer Term Mortality Outcomes in Women with Suspected Ischemic Heart Disease. Journal of Women's Health, 2021, 30, 377-384.	1.5	4
10	An Interprofessional Collaborative Practice Can Reduce Heart Failure Hospital Readmissions and Costs in an Underserved Population. Journal of Cardiac Failure, 2021, 27, 1185-1194.	0.7	6
11	Risk factors for heart failure in women with ischemia and no obstructive coronary artery disease. American Heart Journal Plus, 2021, 8, 100035.	0.3	0
12	Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction. Journal of Clinical Lipidology, 2021, 15, 665-673.	0.6	9
13	Somatic versus cognitive depressive symptoms as predictors of coronary artery disease among women with suspected ischemia: The women's ischemia syndrome evaluation. Heart and Mind (Mumbai, India), 2021, 5, 112.	0.2	4
14	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. European Heart Journal, 2020, 41, 2248-2258.	1.0	51
15	When Diastole Lets You Down: Clinical Relevance of a Widened Pulse Pressure. Canadian Journal of Cardiology, 2020, 36, 593-595.	0.8	0
16	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. European Heart Journal, 2020, 41, 4245-4255.	1.0	117
17	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. European Heart Journal, 2020, 41, 4114-4123.	1.0	35
18	Not typical angina and mortality in women with obstructive coronary artery disease: Results from the Women's Ischemic Syndrome Evaluation study (WISE). IJC Heart and Vasculature, 2020, 27, 100502.	0.6	5

#	Article	IF	CITATIONS
19	Residual risk for coronary heart disease events and mortality despite intensive medical management after myocardial infarction. Journal of Clinical Lipidology, 2020, 14, 260-270.	0.6	11
20	Psychological stress, cardiac symptoms, and cardiovascular risk in women with suspected ischaemia but no obstructive coronary disease. Stress and Health, 2020, 36, 264-273.	1.4	10
21	Response by Schwartz et al to Letter Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial― Circulation, 2020. 142. e335-e336.	1.6	1
22	Association of Region and Hospital and Patient Characteristics With Use of High-Intensity Statins After Myocardial Infarction Among Medicare Beneficiaries. JAMA Cardiology, 2019, 4, 865.	3.0	20
23	Implications for REDUCE IT in clinical practice. Progress in Cardiovascular Diseases, 2019, 62, 395-400.	1.6	12
24	PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults. Journal of Lipid Research, 2019, 60, 1946-1952.	2.0	8
25	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal, 2019, 40, 2801-2809.	1.0	45
26	Impact of Abnormal Coronary Reactivity on Long-Term Clinical Outcomes inÂWomen. Journal of the American College of Cardiology, 2019, 73, 684-693.	1.2	152
27	Sex Differences in High-Intensity Statin Use Following Myocardial Infarction inÂtheÂUnitedÂStates. Journal of the American College of Cardiology, 2018, 71, 1729-1737.	1.2	103
28	Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation, 2018, 137, e30-e66.	1.6	500
29	Weight cycling and cardiovascular outcome in women with suspected ischemia: A report from the NHLBI-sponsored WISE Study. PLoS ONE, 2018, 13, e0207223.	1.1	5
30	A National Study of U.S. Emergency Departments: Racial Disparities in Hospitalizations for Heart Failure. American Journal of Preventive Medicine, 2018, 55, S31-S39.	1.6	25
31	Racial differences in recurrent ischemic stroke risk and recurrent stroke case fatality. Neurology, 2018, 91, e1741-e1750.	1.5	38
32	Cardiac Rehabilitation for Women. Advances in Experimental Medicine and Biology, 2018, 1065, 565-577.	0.8	15
33	Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: A pooled analysis of three federally-funded randomized trials. Atherosclerosis, 2018, 277, 186-194.	0.4	13
34	Migraine Headache and Long-Term Cardiovascular Outcomes: An Extended Follow-Up of the Women's Ischemia Syndrome Evaluation. American Journal of Medicine, 2017, 130, 738-743.	0.6	33
35	Racial differences in statin adherence following hospital discharge for ischemic stroke. Neurology, 2017, 88, 1839-1848.	1.5	16
36	Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries. JAMA Cardiology, 2017, 2, 890.	3.0	95

#	Article	IF	CITATIONS
37	Menopausal symptoms and cardiovascular disease mortality in the Women's Ischemia Syndrome Evaluation (WISE). Menopause, 2017, 24, 126-132.	0.8	58
38	Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011Âto 2014. Journal of the American College of Cardiology, 2017, 69, 2696-2706.	1.2	70
39	Socioeconomic and partner status in chronic heart failure: Relationship to exercise capacity, quality of life, and clinical outcomes. American Heart Journal, 2017, 183, 54-61.	1.2	33
40	Age and Sex Disparities in Discharge Statin Prescribing in the Stroke Belt: Evidence From the Reasons for Geographic and Racial Differences in Stroke Study. Journal of the American Heart Association, 2017, 6, .	1.6	10
41	Inflammatory biomarkers as predictors of heart failure in women without obstructive coronary artery disease: A report from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). PLoS ONE, 2017, 12, e0177684.	1.1	43
42	Tree-based identification of subgroups for time-varying covariate survival data. Statistical Methods in Medical Research, 2016, 25, 488-501.	0.7	11
43	Carotid artery distensibility and hormone therapy and menopause. Menopause, 2016, 23, 150-157.	0.8	7
44	Higher risk for incident heart failure and cardiovascular mortality among communityâ€dwelling octogenarians without pneumococcal vaccination. ESC Heart Failure, 2016, 3, 11-17.	1.4	21
45	Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease. Journal of the American College of Cardiology, 2016, 68, 985-995.	1.2	52
46	Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?. Circulation, 2016, 134, 1695-1696.	1.6	22
47	Cardiovascular Disease and 10-Year Mortality in Postmenopausal Women with Clinical Features of Polycystic Ovary Syndrome. Journal of Women's Health, 2016, 25, 875-881.	1.5	65
48	Advanced Imaging and Diagnostic Methods in the Assessment of Suspected Ischemic Heart Disease in Women. Current Cardiology Reports, 2016, 18, 84.	1.3	0
49	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Scientific Reports, 2016, 6, 30060.	1.6	25
50	Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies. Circulation, 2016, 133, 256-264.	1.6	80
51	Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels. Endocrinology and Metabolism Clinics of North America, 2016, 45, 171-184.	1.2	1
52	Prognostic Significance of Depression in Blacks With Heart Failure. Circulation: Heart Failure, 2015, 8, 497-503.	1.6	14
53	Relationship of physical activity and healthy eating with mortality and incident heart failure among communityâ€dwelling older adults with normal body mass index. ESC Heart Failure, 2015, 2, 20-24.	1.4	13
54	Selecting Patients for Statin Therapy inÂPrimary Prevention. Journal of the American College of Cardiology, 2015, 66, 2710-2712.	1.2	1

#	Article	IF	CITATIONS
55	Underutilization of High-Intensity Statin Therapy After Hospitalization for CoronaryÂHeart Disease. Journal of the American College of Cardiology, 2015, 65, 270-277.	1.2	136
56	Chest Pain Characteristics and Gender in the Early Diagnosis of Acute Myocardial Infarction. Current Cardiology Reports, 2015, 17, 5.	1.3	36
57	Impact of Gait Speed and Instrumental Activities of Daily Living on All-Cause Mortality in Adults ≥65ÂYears With Heart Failure. American Journal of Cardiology, 2015, 115, 797-801.	0.7	66
58	Risk of Heart Failure and Death After Prolonged Smoking Cessation. Circulation: Heart Failure, 2015, 8, 694-701.	1.6	57
59	Heart Failure as a Newly Approved Diagnosis for Cardiac Rehabilitation. Journal of the American College of Cardiology, 2015, 65, 2652-2659.	1.2	77
60	COCATS 4 Task Force 2: Training in Preventive Cardiovascular Medicine. Journal of the American College of Cardiology, 2015, 65, 1754-1762.	1.2	17
61	Statin Use Following Hospitalization Among Medicare Beneficiaries With a Secondary Discharge Diagnosis of Acute Myocardial Infarction. Journal of the American Heart Association, 2015, 4, .	1.6	11
62	Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels. Cardiology Clinics, 2015, 33, 299-308.	0.9	3
63	Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease. Journal of the American College of Cardiology, 2015, 66, 1864-1872.	1.2	24
64	Comprehensive Cardiovascular Risk FactorÂControlÂImproves Survival. Journal of the American College of Cardiology, 2015, 66, 765-773.	1.2	107
65	Trends in mortality and recurrent coronary heart disease events after an acute myocardial infarction among Medicare beneficiaries, 2001-2009. American Heart Journal, 2015, 170, 249-255.e2.	1.2	43
66	The Association Between Life-Space and Health Care Utilization in Older Adults with Heart Failure. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 1442-1447.	1.7	23
67	Lifestyle Interventions for Primary and Secondary Prevention of Cardiovascular Disease. , 2015, , 1695-1718.		2
68	Lipid-Lowering Therapy in Patients 75 Years and Older: Clinical Priority or Superfluous Therapy?. Progress in Cardiovascular Diseases, 2014, 57, 187-196.	1.6	10
69	An assessment by the Statin Cognitive Safety Task Force: 2014 update. Journal of Clinical Lipidology, 2014, 8, S5-S16.	0.6	92
70	Functional Status and Outcome After Coronary Artery Bypass Grafting â^—. JACC: Heart Failure, 2014, 2, 344-346.	1.9	3
71	Ability of Low Antihypertensive Medication Adherence to Predict Statin Discontinuation and Low Statin Adherence in Patients Initiating Treatment After a Coronary Event. American Journal of Cardiology, 2014, 114, 826-831.	0.7	31
72	Discordance between high non-HDL cholesterol and high LDL-cholesterol among US adults. Journal of Clinical Lipidology, 2014, 8, 86-93.	0.6	36

#	Article	IF	CITATIONS
73	Effects of Exercise Training on Outcomes inÂWomen With Heart Failure. JACC: Heart Failure, 2014, 2, 180-186.	1.9	40
74	Achievement of Optimal Medical Therapy Goals for U.S. Adults With Coronary Artery Disease. Journal of the American College of Cardiology, 2014, 63, 1626-1633.	1.2	31
75	Lifestyle Interventions for Primary and Secondary Prevention of Cardiovascular Disease. , 2014, , 1-29.		0
76	Reply. Journal of the American College of Cardiology, 2013, 61, 2113.	1.2	3
77	Race, exercise training, and outcomes in chronic heart failure: Findings from Heart Failure - A Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION). American Heart Journal, 2013, 166, 488-495.e1.	1.2	29
78	Risk Factor Control for Coronary Artery Disease Secondary Prevention in Large Randomized Trials. Journal of the American College of Cardiology, 2013, 61, 1607-1615.	1.2	137
79	Prevention of heart failure in older adults may require higher levels of physical activity than needed for other cardiovascular events. International Journal of Cardiology, 2013, 168, 1905-1909.	0.8	34
80	Anxiety associations with cardiac symptoms, angiographic disease severity, and healthcare utilization: The NHLBI-sponsored Women's Ischemia Syndrome Evaluation. International Journal of Cardiology, 2013, 168, 2335-2340.	0.8	27
81	LDL Lowering After Acute Coronary Syndrome: Is Lower Better?. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 33-40.	0.4	6
82	Trends in the Prevalence, Awareness, Treatment and Control of High Low Density Lipoprotein-Cholesterol Among United States Adults From 1999–2000 Through 2009–2010. American Journal of Cardiology, 2013, 112, 664-670.	0.7	58
83	Clinical Implications of the Women's Ischemia Syndrome Evaluation: Inter-Relationships Between Symptoms, Psychosocial Factors and Cardiovascular Outcomes. Women's Health, 2013, 9, 479-490.	0.7	32
84	Anginal Symptoms, Coronary Artery Disease, and Adverse Outcomes in Black and White Women: The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Journal of Women's Health, 2013, 22, 724-732.	1.5	55
85	Secondary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults. Circulation, 2013, 128, 2422-2446.	1.6	166
86	Left Ventricular Energy Model Predicts Adverse Events in Women With Suspected Myocardial Ischemia: Results From The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Cardiovascular Diagnosis and Therapy, 2013, 3, 64-72.	0.7	15
87	Cardiac Rehabilitation. Circulation, 2012, 126, 671-673.	1.6	7
88	Medical Director Responsibilities for Outpatient Cardiac Rehabilitation/Secondary Prevention Programs. Journal of Cardiopulmonary Rehabilitation and Prevention, 2012, 32, 410-419.	1.2	8
89	Increasing Referral and Participation Rates to Outpatient Cardiac Rehabilitation: The Valuable Role of Healthcare Professionals in the Inpatient and Home Health Settings. Circulation, 2012, 125, 1321-1329.	1.6	162
90	Population Approaches to Improve Diet, Physical Activity, and Smoking Habits. Circulation, 2012, 126, 1514-1563.	1.6	488

VERA BITTNER

#	Article	IF	CITATIONS
91	Relationships Between Cardiovascular Disease Risk Factors and Depressive Symptoms as Predictors of Cardiovascular Disease Events in Women. Journal of Women's Health, 2012, 21, 133-139.	1.5	34
92	Combining Psychosocial Data to Improve Prediction of Cardiovascular Disease Risk Factors and Events. Psychosomatic Medicine, 2012, 74, 263-270.	1.3	20
93	6-Min Walk Test Provides Prognostic Utility Comparable to Cardiopulmonary Exercise Testing in Ambulatory Outpatients With Systolic Heart Failure. Journal of the American College of Cardiology, 2012, 60, 2653-2661.	1.2	171
94	Medical Director Responsibilities for Outpatient Cardiac Rehabilitation/Secondary Prevention Programs: 2012 Update. Circulation, 2012, 126, 2535-2543.	1.6	19
95	Triglycerides and Cardiovascular Disease. Circulation, 2011, 123, 2292-2333.	1.6	1,511
96	Gender-related dissociation in outcomes in chronic heart failure: Reduced mortality but similar hospitalization in women. International Journal of Cardiology, 2011, 148, 36-42.	0.8	15
97	Timing of hormone therapy, type of menopause, and coronary disease in women. Menopause, 2011, 18, 943-950.	0.8	29
98	Efficacy of Fenofibric Acid Plus Statins on Multiple Lipid Parameters and Its Safety in Women With Mixed Dyslipidemia. American Journal of Cardiology, 2011, 107, 898-905.	0.7	8
99	Sex, Clinical Symptoms, and Angiographic Findings in Patients With Diabetes Mellitus and Coronary Artery Disease (from the Bypass Angioplasty Revascularization Investigation [BARI] 2 Diabetes Trial). American Journal of Cardiology, 2011, 107, 980-985.	0.7	18
100	Ageing, menopause, and ischaemic heart disease mortality in England, Wales, and the United States: modelling study of national mortality data. BMJ: British Medical Journal, 2011, 343, d5170-d5170.	2.4	60
101	Cardiac Rehabilitation Outcomes. Journal of Cardiopulmonary Rehabilitation and Prevention, 2011, 31, 342-348.	1.2	49
102	Isolated Diastolic Hypotension and Incident Heart Failure in Older Adults. Hypertension, 2011, 58, 895-901.	1.3	44
103	Self-Rated Versus Objective Health Indicators as Predictors of Major Cardiovascular Events: The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation. Psychosomatic Medicine, 2010, 72, 549-555.	1.3	44
104	Cardiac Rehabilitation and Women. Journal of Cardiopulmonary Rehabilitation and Prevention, 2010, 30, 12-21.	1.2	39
105	Exercise as a Treatment for the Risk of Cardiovascular Disease. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 329-341.	0.4	2
106	Usefulness of Heart Rate at Rest as a Predictor of Mortality, Hospitalization for Heart Failure, Myocardial Infarction, and Stroke in Patients With Stable Coronary Heart Disease (Data from the) Tj ETQq0 0 0 r	gB ð.¦O verl	oc k 010 Tf 50
107	Effects of Right Ventricular Ejection Fraction on Outcomes in Chronic Systolic Heart Failure. Circulation, 2010, 121, 252-258.	1.6	270

The Relationship of Menopausal Status and Rapid Menopausal Transition with Carotid Intima-Media108Thickness Progression in Women: A Report from the Los Angeles Atherosclerosis Study. Journal of1.825Clinical Endocrinology and Metabolism, 2010, 95, 4432-4440.1.825

VERA BITTNER

#	Article	IF	CITATIONS
109	DHEA-S Levels and Cardiovascular Disease Mortality in Postmenopausal Women: Results from the National Institutes of Health—National Heart, Lung, and Blood Institute (NHLBI)-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4985-4992.	1.8	101
110	Assessing and addressing risk of cardiovascular disease in perimenopausal and early postmenopausal women. Journal of Clinical Lipidology, 2010, 4, 324-334.	0.6	1
111	Prognostic Value of Global MR Myocardial Perfusion Imaging in Women With Suspected Myocardial Ischemia and No Obstructive Coronary Disease. JACC: Cardiovascular Imaging, 2010, 3, 1030-1036.	2.3	94
112	Variations in prevalent cardiovascular disease and future risk by metabolic syndrome classification in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. American Heart Journal, 2010, 159, 385-391.	1.2	21
113	The Joint Impact of Smoking and Exercise Capacity on Clinical Outcomes among Women with Suspected Myocardial Ischemia: The WISE Study. Journal of Women's Health, 2009, 18, 443-450.	1.5	4
114	Postmenopausal hormone therapy and the risk of cardiovascular disease. Expert Opinion on Pharmacotherapy, 2009, 10, 2041-2053.	0.9	5
115	AHA/ACCF 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults. Circulation, 2009, 120, 1296-1336.	1.6	117
116	Depressive Symptom Dimensions and Cardiovascular Prognosis Among Women With Suspected Myocardial Ischemia. Archives of General Psychiatry, 2009, 66, 499.	13.8	116
117	Control of Lipids at Baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI) Tj ETQq1	10.7843 1.1	314 rgBT /O
118	Drugs Are Not Enough: The Metabolic Syndrome—A Call for Intensive Therapeutic Lifestyle Change. Journal of the Cardiometabolic Syndrome, 2009, 4, 20-25.	1.7	9
119	Biomarkers of atherosclerosis: Clinical applications. Current Cardiovascular Risk Reports, 2009, 3, 23-30.	0.8	2
120	The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia. American Heart Journal, 2009, 157, 548-555.	1.2	192
121	Baseline differences in the HF-ACTION trial by sex. American Heart Journal, 2009, 158, S16-S23.	1.2	40
122	Depression and Cardiovascular Health Care Costs Among Women With Suspected Myocardial Ischemia. Journal of the American College of Cardiology, 2009, 53, 176-183.	1.2	80
123	Predictors of Cardiac Rehabilitation Referral in Coronary Artery Disease Patients. Journal of the American College of Cardiology, 2009, 54, 515-521.	1.2	236
124	ACCF/AHA 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults. Journal of the American College of Cardiology, 2009, 54, 1364-1405.	1.2	80
125	Menopause, Age, and Cardiovascular Risk. Journal of the American College of Cardiology, 2009, 54, 2374-2375.	1.2	76
126	Total Estrogen Time and Obstructive Coronary Disease in Women: Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Journal of Women's Health, 2009, 18, 1315-1322.	1.5	30

#	Article	IF	CITATIONS
127	Assessing Patient Recall of Discharge Instructions for Acute Myocardial Infarction. Journal for Healthcare Quality: Official Publication of the National Association for Healthcare Quality, 2009, 31, 25-34.	0.3	20
128	Comparison of Baseline Characteristics and Outcomes in Younger and Older Patients Completing Cardiac Rehabilitation. Journal of Cardiopulmonary Rehabilitation and Prevention, 2009, 29, 220-229.	1.2	21
129	Comorbid Depression and Anxiety Symptoms as Predictors of Cardiovascular Events: Results From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Psychosomatic Medicine, 2009, 71, 958-964.	1.3	104
130	Biomarkers of atherosclerosis: Clinical applications. Current Cardiology Reports, 2008, 10, 497-504.	1.3	34
131	Health-related Quality of Life Following Coronary Artery Bypass Graft Surgery in Post-menopausal Women. Journal of General Internal Medicine, 2008, 23, 1429-1434.	1.3	7
132	Diabetes Mellitus, Hypothalamic Hypoestrogenemia, and Coronary Artery Disease in Premenopausal Women (from the National Heart, Lung, and Blood Institute Sponsored WISE Study). American Journal of Cardiology, 2008, 102, 150-154.	0.7	29
133	Comparison of Effectiveness of Atorvastatin 10 mg Versus 80 mg in Reducing Major Cardiovascular Events and Repeat Revascularization in Patients With Previous Percutaneous Coronary Intervention (Post Hoc Analysis of the Treating to New Targets [TNT] Study). American Journal of Cardiology, 2008, 102. 1312-1317.	0.7	40
134	Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. Journal of Translational Medicine, 2008, 6, 11.	1.8	22
135	Depression, the Metabolic Syndrome and Cardiovascular Risk. Psychosomatic Medicine, 2008, 70, 40-48.	1.3	150
136	Task Force 10: Training in Preventive Cardiovascular Medicine. Journal of the American College of Cardiology, 2008, 51, 393-398.	1.2	9
137	Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease. Journal of the American College of Cardiology, 2008, 51, 1448-1454.	1.2	291
138	Relations between Endogenous Androgens and Estrogens in Postmenopausal Women with Suspected Ischemic Heart Disease. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4268-4275.	1.8	24
139	Importance of Socioeconomic Status as a Predictor of Cardiovascular Outcome and Costs of Care in Women with Suspected Myocardial Ischemia. Results from the National Institutes of Health, National Heart, Lung and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Journal of Women's Health. 2008. 17, 1081-1092.	1.5	43
140	Does Prevalence of the Metabolic Syndrome in Women with Coronary Artery Disease Differ by the ATP III and IDF Criteria?. Journal of Women's Health, 2008, 17, 841-847.	1.5	21
141	Social Networks and Incident Stroke Among Women With Suspected Myocardial Ischemia. Psychosomatic Medicine, 2008, 70, 282-287.	1.3	69
142	Analyzing the Results of the Treating to New Targets Study. Annals of Internal Medicine, 2008, 148, 322.	2.0	0
143	Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1131-1139.	2.2	246
144	Core Components of Cardiac Rehabilitation/Secondary Prevention Programs: 2007 Update. Circulation, 2007, 115, 2675-2682.	1.6	933

#	Article	IF	CITATIONS
145	Core Components of Cardiac Rehabilitation/Secondary Prevention Programs: 2007 Update. Journal of Cardiopulmonary Rehabilitation and Prevention, 2007, 27, 121-129.	1.2	206
146	Fasting Plasma Glucose Predicts Survival And Angiographic Progression in High-Risk Postmenopausal Women with Coronary Artery Disease. Journal of Women's Health, 2007, 16, 228-234.	1.5	1
147	Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure. Circulation, 2007, 115, 576-583.	1.6	159
148	Influenza Vaccination in Secondary Prevention-An Opportunity Missed. Journal of Cardiopulmonary Rehabilitation and Prevention, 2007, 27, 202-207.	1.2	5
149	Outcomes at One-Year Follow-up of Women and Men With Coronary Artery Disease Discharged From Cardiac Rehabilitation. Journal of Cardiopulmonary Rehabilitation and Prevention, 2007, 27, 11-18.	1.2	47
150	Secondary prevention outcomes among black and white cardiac rehabilitation patients. American Heart Journal, 2007, 153, 980-986.	1.2	17
151	Transthoracic Echocardiography Guided Procedures in the Catheterization Laboratory. Echocardiography, 2007, 24, 1000-1007.	0.3	5
152	HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. New England Journal of Medicine, 2007, 357, 1301-1310.	13.9	1,390
153	Resistance Exercise in Individuals With and Without Cardiovascular Disease: 2007 Update. Circulation, 2007, 116, 572-584.	1.6	976
154	Depression, Inflammation, and Incident Cardiovascular Disease in Women With Suspected Coronary Ischemia. Journal of the American College of Cardiology, 2007, 50, 2044-2050.	1.2	234
155	Management of stable patients with coronary heart disease: Clinical implications of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial. Journal of Clinical Lipidology, 2007, 1, 564-574.	0.6	5
156	Role of the 6-Minute Walk Test in Cardiac Rehabilitation. , 2007, , 131-139.		7
157	Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Journal of the American College of Cardiology, 2006, 47, S21-S29.	1.2	727
158	Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Journal of the American College of Cardiology, 2006, 47, S4-S20.	1.2	620
159	Hypertension, Menopause, and Coronary Artery Disease Risk in the Women's Ischemia Syndrome Evaluation (WISE) Study. Journal of the American College of Cardiology, 2006, 47, S50-S58.	1.2	88
160	Migraines, Angiographic Coronary Artery Disease and Cardiovascular Outcomes in Women. American Journal of Medicine, 2006, 119, 670-675.	0.6	49
161	The Relation of Postmenopausal Hormone Therapy to Serum Uric Acid and the Risk of Coronary Heart Disease Events: The Heart and Estrogen–Progestin Replacement Study (HERS). Annals of Epidemiology, 2006, 16, 138-145.	0.9	39
162	Prediction of medical morbidity and mortality after acute myocardial infarction in patients at increased psychosocial risk in the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) study. American Heart Journal, 2006, 152, 126-135.	1.2	66

#	Article	IF	CITATIONS
163	Self-rated health among women with coronary disease: Depression is as important as recent cardiovascular events. American Heart Journal, 2006, 152, 921.e1-921.e7.	1.2	27
164	Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation. Fertility and Sterility, 2006, 85, 1425-1431.	0.5	69
165	Cardiac rehabilitation as secondary prevention center. Coronary Artery Disease, 2006, 17, 211-218.	0.3	9
166	Practical Interpretation of 6-Minute Walk Data Using Healthy Adult Reference Equations. Journal of Cardiopulmonary Rehabilitation and Prevention, 2006, 26, 167-171.	0.5	7
167	Perspectives on dyslipidemia and coronary heart disease in women: an update. Current Opinion in Cardiology, 2006, 21, 602-607.	0.8	13
168	The Economic Burden of Angina in Women With Suspected Ischemic Heart Disease. Circulation, 2006, 114, 894-904.	1.6	299
169	Phytoestrogens and Lipoproteins in Women. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2209-2213.	1.8	26
170	Obesity Distribution and Reproductive Hormone Levels in Women: A Report from the NHLBI-Sponsored WISE Study. Journal of Women's Health, 2006, 15, 836-842.	1.5	23
171	Women and Coronary Heart Disease. Fundamental and Clinical Cardiology, 2006, , 689-720.	0.0	Ο
172	Impaired Fasting Glucose and Cardiovascular Outcomes in Postmenopausal Women with Coronary Artery Disease. Annals of Internal Medicine, 2005, 142, 813.	2.0	62
173	Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study. European Heart Journal, 2005, 27, 1408-1415.	1.0	238
174	Dietitian Services Are Associated with Improved Patient Outcomes and the MEDFICTS Dietary Assessment Questionnaire Is a Suitable Outcome Measure in Cardiac Rehabilitation. Journal of the American Dietetic Association, 2005, 105, 1533-1540.	1.3	40
175	Depression and heart failure in patients with a new myocardial infarction. American Heart Journal, 2005, 149, 851-855.	1.2	21
176	Women in cardiac rehabilitation: Outcomes and identifying risk for dropout. American Heart Journal, 2005, 150, 1052-1058.	1.2	83
177	Outcomes in patients with chronic kidney disease undergoing cardiac rehabilitation. American Heart Journal, 2005, 150, 1140-1146.	1.2	36
178	Perspectives on Dyslipidemia and Coronary Heart Disease in Women. Journal of the American College of Cardiology, 2005, 46, 1628-1635.	1.2	67
179	The Effect of Vitamin Therapy on the Progression of Coronary Artery Atherosclerosis Varies by Haptoglobin Type in Postmenopausal Women. Diabetes Care, 2004, 27, 925-930.	4.3	50
180	Determination of Menopausal Status in Women: The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Journal of Women's Health, 2004, 13, 872-887.	1.5	67

#	Article	IF	CITATIONS
181	Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B. American Journal of Cardiology, 2004, 94, 219-222.	0.7	132
182	Knowledge of heart attack symptoms in 20 US communities. Results from the rapid early action for coronary treatment community trial. Preventive Medicine, 2004, 38, 85-93.	1.6	46
183	Remnant-like lipoproteins, hormone therapy, and angiographic and clinical outcomes: The Women's Angiographic Vitamin & Estrogen trial. American Heart Journal, 2004, 148, 293-299.	1.2	8
184	Nonâ€Highâ€Density Lipoprotein Cholesterol: An Alternate Target for Lipid‣owering Therapy. Preventive Cardiology, 2004, 7, 122-130.	1.1	15
185	Optimizing Risk Stratification in Cardiac Rehabilitation With Inclusion of a Comorbidity Index. Journal of Cardiopulmonary Rehabilitation and Prevention, 2004, 24, 8-13.	0.5	23
186	Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. Journal of the American College of Cardiology, 2003, 41, 413-419.	1.2	221
187	Exercise testing in heart failure. Journal of the American College of Cardiology, 2003, 42, 123-125.	1.2	9
188	The 6-minute walk test: How important is the learning effect?. American Heart Journal, 2003, 146, 129-133.	1.2	168
189	Metabolic syndrome and coronary angiographic disease progression: the Women's Angiographic Vitamin & Estrogen trial. American Heart Journal, 2003, 146, 439-445.	1.2	41
190	Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS). American Heart Journal, 2003, 146, 870-875.	1.2	38
191	Personal, social, and physical environmental correlates of physical activity in rural African-American women in Alabama. American Journal of Preventive Medicine, 2003, 25, 30-37.	1.6	61
192	The 6-min Walk Test*. Chest, 2003, 123, 387-398.	0.4	673
193	Physical Activity Patterns Among Women in Rural Alabama. American Journal of Health Behavior, 2003, 27, 311-321.	0.6	13
194	Factors Associated With the Failure of Patients to Complete Cardiac Rehabilitation for Medical and Nonmedical Reasons. Journal of Cardiopulmonary Rehabilitation and Prevention, 2003, 23, 281-289.	0.5	67
195	Non-high-density lipoprotein cholesterol and cardiovascular disease. Current Opinion in Lipidology, 2003, 14, 367-371.	1.2	16
196	Factor V Leiden, Hormone Replacement Therapy, and Risk of Venous Thromboembolic Events in Women With Coronary Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1012-1017.	1.1	144
197	Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy. JAMA - Journal of the American Medical Association, 2002, 288, 49.	3.8	1,586
198	Non–High-Density Lipoprotein Cholesterol Levels Predict Five-Year Outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation, 2002, 106, 2537-2542.	1.6	167

#	Article	IF	CITATIONS
199	Statin Therapy, Cardiovascular Events, and Total Mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation, 2002, 105, 2962-2967.	1.6	223
200	Effects of Hormone Replacement Therapy and Antioxidant Vitamin Supplements on Coronary Atherosclerosis in Postmenopausal Women. JAMA - Journal of the American Medical Association, 2002, 288, 2432.	3.8	500
201	Cholesterol-lowering medication, cholesterol level, and reproductive hormones in women: the women's ischemia syndrome evaluation (WISE). American Journal of Medicine, 2002, 113, 723-727.	0.6	23
202	Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart and Lung: Journal of Acute and Critical Care, 2002, 31, 262-270.	0.8	329
203	Prehospital Delay in Individuals with Acute Coronary Disease: Concordance of Medical Records and Follow-Up Phone Interviews. Cardiology, 2002, 97, 159-165.	0.6	9
204	Lipoprotein abnormalities related to women's health. American Journal of Cardiology, 2002, 90, 77-84.	0.7	80
205	Women's Angiographic Vitamin and Estrogen trial:. Contemporary Clinical Trials, 2002, 23, 708-727.	2.0	21
206	Women and coronary heart disease risk factors. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 315-22.	1.5	8
207	Effect of coronary angiography on use of lipid-lowering agents in women: a report from the women's ischemia syndrome evaluation (WISE) study. American Journal of Cardiology, 2000, 85, 1083-1088.	0.7	18
208	Physical Activity and Functional Capacity Measurement in Women: A Report from the NHLBI-Sponsored WISE Study. Journal of Women's Health and Gender-Based Medicine, 2000, 9, 769-777.	1.7	45
209	Correlates of high HDL cholesterol among women with coronary heart disease. American Heart Journal, 2000, 139, 288-296.	1.2	41
210	Referral patterns to a university-based cardiac rehabilitation program. American Journal of Cardiology, 1999, 83, 252-255.	0.7	74
211	Statistical Design of REACT (Rapid Early Action for Coronary Treatment), a Multisite Community Trial with Continual. Contemporary Clinical Trials, 1998, 19, 391-403.	2.0	32
212	Better Outcome for Women Compared With Men Undergoing Coronary Revascularization. Circulation, 1998, 98, 1279-1285.	1.6	242
213	Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease: A CASS registry study. Journal of the American College of Cardiology, 1995, 25, 1000-1009.	1.2	204
214	Atherogenicity of Postprandial Lipoproteins and Coronary Heart Disease. , 1994, 4, 359-372.		8
215	Prediction of Mortality and Morbidity With a 6-Minute Walk Test in Patients With Left Ventricular Dysfunction. JAMA - Journal of the American Medical Association, 1993, 270, 1702.	3.8	561
216	Efficacy Studies in Coronary Rehabilitation. Cardiology Clinics, 1993, 11, 333-347.	0.9	15

#	Article	IF	CITATIONS
217	Dual connection of the left anterior descending coronary artery to the left and right coronary arteries. Catheterization and Cardiovascular Diagnosis, 1989, 16, 168-172.	0.7	13